布鲁顿酪氨酸激酶抑制剂在COVID-19治疗中的可能作用综述

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Current Therapeutic Research-clinical and Experimental Pub Date : 2022-01-01 DOI:10.1016/j.curtheres.2021.100658

Mitra Rezaei MD , Saghar Barati Pharm-D, PhD , Abdolreza Babamahmoodi MD , Farzaneh Dastan Pharm-D, PhD , Majid Marjani MD

{"title":"布鲁顿酪氨酸激酶抑制剂在COVID-19治疗中的可能作用综述","authors":"Mitra Rezaei MD , Saghar Barati Pharm-D, PhD , Abdolreza Babamahmoodi MD , Farzaneh Dastan Pharm-D, PhD , Majid Marjani MD","doi":"10.1016/j.curtheres.2021.100658","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Coronavirus disease 2019 (COVID-19), an acute, sometimes severe respiratory illness caused by a novel coronavirus has led to a vast pandemic with an astonishing spread rate. Its treatment is unknown, its mortality is significant, and its socioeconomic complications are uncontrollable. Although there is still little known about the pathogenesis of the disease, severe cases of COVID-19 are usually associated with cytokine release syndrome and high serum levels of inflammatory cytokines, which are believed to be a major cause of mortality in these patients. Different pathways cause inflammation and the release of cytokines. One of these pathways is the Bruton tyrosine kinase (BTK) pathway, which is essential for the production of several anti-inflammatory cytokines. Theoretically, the inhibition of BTK signaling can reduce cytokine levels and subsequent anti-inflammatory effects.</p></div><div><h3>Objective</h3><p>This review aims to investigate the role of the BTK pathway in the pathogenesis of COVID-19 and the possible effects of its inhibition in the treatment of this disease.</p></div><div><h3>Methods</h3><p>This narrative review provides information regarding the use of BTK inhibitors in patients with COVID-19 and discusses whether clinicians should consider these medications while managing their patients based on the literature. Data were gathered using the PubMed, Scopus, and Web of Science databases.</p></div><div><h3>Results</h3><p>Some data support the use of BTK inhibitors for treating COVID-19.</p></div><div><h3>Conclusions</h3><p>It is recommended that patients continue their medications in this class if they develop COVID-19 and were receiving these agents before the disease developed. The use of BTK inhibitors might enable patients to experience less severe immune responses to the COVID-19. Well-designed studies are needed to evaluate the effectiveness of BTKis in the management of COVID-19. (Curr Ther Res Clin Exp. 2022; 82:XXX–XXX) © 2022 Elsevier HS Journals</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"96 ","pages":"Article 100658"},"PeriodicalIF":1.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/4a/main.PMC8673731.pdf","citationCount":"10","resultStr":"{\"title\":\"The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review\",\"authors\":\"Mitra Rezaei MD , Saghar Barati Pharm-D, PhD , Abdolreza Babamahmoodi MD , Farzaneh Dastan Pharm-D, PhD , Majid Marjani MD\",\"doi\":\"10.1016/j.curtheres.2021.100658\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Coronavirus disease 2019 (COVID-19), an acute, sometimes severe respiratory illness caused by a novel coronavirus has led to a vast pandemic with an astonishing spread rate. Its treatment is unknown, its mortality is significant, and its socioeconomic complications are uncontrollable. Although there is still little known about the pathogenesis of the disease, severe cases of COVID-19 are usually associated with cytokine release syndrome and high serum levels of inflammatory cytokines, which are believed to be a major cause of mortality in these patients. Different pathways cause inflammation and the release of cytokines. One of these pathways is the Bruton tyrosine kinase (BTK) pathway, which is essential for the production of several anti-inflammatory cytokines. Theoretically, the inhibition of BTK signaling can reduce cytokine levels and subsequent anti-inflammatory effects.</p></div><div><h3>Objective</h3><p>This review aims to investigate the role of the BTK pathway in the pathogenesis of COVID-19 and the possible effects of its inhibition in the treatment of this disease.</p></div><div><h3>Methods</h3><p>This narrative review provides information regarding the use of BTK inhibitors in patients with COVID-19 and discusses whether clinicians should consider these medications while managing their patients based on the literature. Data were gathered using the PubMed, Scopus, and Web of Science databases.</p></div><div><h3>Results</h3><p>Some data support the use of BTK inhibitors for treating COVID-19.</p></div><div><h3>Conclusions</h3><p>It is recommended that patients continue their medications in this class if they develop COVID-19 and were receiving these agents before the disease developed. The use of BTK inhibitors might enable patients to experience less severe immune responses to the COVID-19. Well-designed studies are needed to evaluate the effectiveness of BTKis in the management of COVID-19. (Curr Ther Res Clin Exp. 2022; 82:XXX–XXX) © 2022 Elsevier HS Journals</p></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"96 \",\"pages\":\"Article 100658\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/4a/main.PMC8673731.pdf\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X21000369\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X21000369","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 10

摘要

2019冠状病毒病(COVID-19)是一种由新型冠状病毒引起的急性，有时是严重的呼吸道疾病，已导致大规模流行，传播速度惊人。其治疗方法尚不清楚，死亡率很高，其社会经济并发症无法控制。尽管对该病的发病机制知之甚少，但严重的COVID-19病例通常与细胞因子释放综合征和血清炎症细胞因子水平高有关，这被认为是这些患者死亡的主要原因。不同的途径引起炎症和细胞因子的释放。其中一种途径是布鲁顿酪氨酸激酶(BTK)途径，它对几种抗炎细胞因子的产生至关重要。理论上，抑制BTK信号可以降低细胞因子水平和随后的抗炎作用。目的探讨BTK通路在COVID-19发病机制中的作用及其抑制在该病治疗中的可能作用。方法本叙述性综述提供了有关COVID-19患者使用BTK抑制剂的信息，并根据文献讨论了临床医生在管理患者时是否应考虑使用这些药物。使用PubMed、Scopus和Web of Science数据库收集数据。结果部分数据支持使用BTK抑制剂治疗COVID-19。结论如果患者感染了COVID-19，并且在发病前已经接受了这些药物治疗，建议继续使用这类药物。使用BTK抑制剂可能使患者对COVID-19的免疫反应不那么严重。需要精心设计的研究来评估BTKis在COVID-19管理中的有效性。(中国临床医学杂志，2022;82: XXX-XXX)©2022 Elsevier HS Journals

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review

Background

Coronavirus disease 2019 (COVID-19), an acute, sometimes severe respiratory illness caused by a novel coronavirus has led to a vast pandemic with an astonishing spread rate. Its treatment is unknown, its mortality is significant, and its socioeconomic complications are uncontrollable. Although there is still little known about the pathogenesis of the disease, severe cases of COVID-19 are usually associated with cytokine release syndrome and high serum levels of inflammatory cytokines, which are believed to be a major cause of mortality in these patients. Different pathways cause inflammation and the release of cytokines. One of these pathways is the Bruton tyrosine kinase (BTK) pathway, which is essential for the production of several anti-inflammatory cytokines. Theoretically, the inhibition of BTK signaling can reduce cytokine levels and subsequent anti-inflammatory effects.

Objective

This review aims to investigate the role of the BTK pathway in the pathogenesis of COVID-19 and the possible effects of its inhibition in the treatment of this disease.

Methods

This narrative review provides information regarding the use of BTK inhibitors in patients with COVID-19 and discusses whether clinicians should consider these medications while managing their patients based on the literature. Data were gathered using the PubMed, Scopus, and Web of Science databases.

Results

Some data support the use of BTK inhibitors for treating COVID-19.

Conclusions

It is recommended that patients continue their medications in this class if they develop COVID-19 and were receiving these agents before the disease developed. The use of BTK inhibitors might enable patients to experience less severe immune responses to the COVID-19. Well-designed studies are needed to evaluate the effectiveness of BTKis in the management of COVID-19. (Curr Ther Res Clin Exp. 2022; 82:XXX–XXX) © 2022 Elsevier HS Journals

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.